Contents

Search

bedaquiline (Sirturo)

Indications: - pulmonary tuberculosis, as component of combination therapy for adults with multi-drug resistant tuberculosis, when no satisfactory alternatives remain Dosage: - directly observed oral therapy [6] Storage: - can be dispensed in original container, or a tight, light-resistant container - must be used within 3 months if stored in a container other than the original [5] Adverse effects: - common: nausea, joint pain, headache - QT prolongation - elevated serum transaminases - hemoptysis Laboratory: - bedaquiline in serum/plasma Mechanism of action: - enzyme inhibitor - inhibits Mycobacterial ATP synthase [6]

General

anti-tuberculous agent enzyme inhibitor heterocyclic compound, 2 rings amine alcohol

Database Correlations

PUBCHEM correlations

References

  1. FDA Newe Release: Dec. 31, 2012 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm
  2. World Health Oragnization (WHO). 2013 The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim Policy Guideline. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf - World Health Oragnization (WHO). 2013 WHO interim guidance on the use of bedaquiline to treat MDR-TB https://mail.google.com/mail/u/0/?shva=1#inbox/13f425db09d8dfc1
  3. Mase S et al Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR. October 25, 2013 / 62(rr09);1-12 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm
  4. Deprecated Reference
  5. Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: 300622 (subscription needed) http://www.prescribersletter.com
  6. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015